Bristol-Myers Squibb Company (BMY) 49.52 $BMY
Final Glance: Pharmaceuticals companies
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor.
Midday Glance: Pharmaceuticals companies
AP - Thu May 01, 12:46PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Thu May 01, 10:10AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Metastatic Colorectal Cancer Clinical Trials Review 2014: Espy the Commercial Landscape of the Major Institutes & Companies
M2 - Thu May 01, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jtbsc/metastatic) has announced the addition of the "Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Colorectal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Colorectal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Colorectal Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Pfizer Inc. - E. Merck KG - Eli Lilly and Company - Bristol-Myers Squibb Company - Novartis AG - Bayer AG - AstraZeneca PLC - National Cancer Institute - Memorial Sloan Kettering Cancer Center - The University of Texas M. D. Anderson Cancer Center - Grupo Espanol de Tratamiento de Tumores Digestivos - Epidemiological and Clinical Research Information Network - European Organization for Research and Treatment of Cancer - Gruppo Oncologico del Nord-Ovest - NCIC Clinical Trials Group - Duke University For more information visit http://www.researchandmarkets.com/research/4jtbsc/metastatic
Technical Recap on Pharma Equities -- Research on Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu May 01, 8:16AM CDT
On Wednesday, April 30, 2014, the NASDAQ Composite ended at 4,114.56, up 0.27%, the Dow Jones Industrial Average advanced 0.27%, to finish the day at 16,580.84, and the S&P 500 closed at 1,883.95, up 0.30%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.95, up 0.14%, with the index advancing 3.87% in the previous three months. Investor-Edge has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly & Company (NYSE: LLY) and GlaxoSmithKline PLC (NYSE: GSK). Free technical research on BMY, AZN, LLY and GSK can be downloaded upon signing up at:
Global Metastatic Prostate Cancer Clinical Trials Review 2014: Espy the 20 Leading Companies/Institutions
M2 - Thu May 01, 7:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/thv65g/metastatic) has announced the addition of the "Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Prostate Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Johnson & Johnson - Astellas Pharma Inc. - AstraZeneca PLC - Medivation, Inc. - Sanofi - Ipsen S.A. - Bristol-Myers Squibb Company - Pfizer Inc. - Novartis AG - Eli Lilly and Company - National Cancer Institute - European Organization for Research and Treatment of Cancer - Memorial Sloan Kettering Cancer Center - Barbara Ann Karmanos Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Southwest Oncology Group - OHSU Knight Cancer Institute - Swiss Group for Clinical Cancer Research - National Prostate Cancer Treatment Group - UNICANCER Group For more information visit http://www.researchandmarkets.com/research/thv65g/metastatic
Research and Markets: Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
Business Wire - Thu May 01, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9fbq3/organ) has announced the addition of the "Worldwide Organ Preservation Solutions Market 2013 - 2019" report to their offering.
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - Thu May 01, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Bristol-Myers Squibb's (BMY) CEO John Elicker on Q1 2014 Earnings - Call Transcript
at The Street - Wed Apr 30, 11:26AM CDT
Bristol-Myers Squibb Company (BMY) Q1 2014 Earnings Conference Call - April 29, 2014 9:00 AM ET
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials Review 2014
M2 - Wed Apr 30, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k5m6xs/metastatic) has announced the addition of the "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Co., Ltd. - Boehringer Ingelheim GmbH - Biotest AG - Astellas Pharma Inc. - Altor BioScience Corporation - National Cancer Institute - The University of Chicago - European Organization for Research and Treatment of Cancer - Icahn School of Medicine at Mount Sinai - Memorial Sloan Kettering Cancer Center - Barts and The London NHS Trust - The Wales Cancer Trials Unit - Northern California Cancer Center - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/k5m6xs/metastatic
Papillary Renal Cell Carcinoma Clinical Trials Review 2014
M2 - Wed Apr 30, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2qftt/papillary_renal) has announced the addition of the "Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" report to their offering. Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Papillary Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Papillary Renal Cell Carcinoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Astellas Pharma Inc. - National Cancer Institute - Fox Chase Cancer Center - Memorial Sloan Kettering Cancer Center - UNICANCER Group - Austrian Urogynecology Working Group - Ohio State University Comprehensive Cancer Center - Fred Hutchinson Cancer Research Center - Children's Oncology Group For more information visit http://www.researchandmarkets.com/research/m2...lary_renal
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management
PRWeb - Wed Apr 30, 2:25AM CDT
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Chemical Development Summit, held April 23 - 24, 2014 at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. The meeting featured a tour of the BMS high throughput lab, customer case studies, and discussions of best practices in high throughput research and data management.
Bristol, Merck Q1 sales soft
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Bristol-Myers Squibb (BMY) said EPS rose 12% to 46 cents, beating views by 3 cents. But sales fell 1% to $3.8 bil, missing views of $3.9 bil. Bristol raised the low end of its full-year EPS guidance to $1.65-$1.80, but the midpoint is below analysts'...
Final Glance: Pharmaceuticals companies
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
CRL for The Medicines Co.'s Cangrelor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:05PM CDT
The FDA issued a CRL to The Medicines Co.'s (MDCO) NDA for cangrelor.
Midday Glance: Pharmaceuticals companies
AP - Thu May 01, 12:46PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Thu May 01, 10:10AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Metastatic Colorectal Cancer Clinical Trials Review 2014: Espy the Commercial Landscape of the Major Institutes & Companies
M2 - Thu May 01, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jtbsc/metastatic) has announced the addition of the "Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Colorectal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Colorectal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Colorectal Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Pfizer Inc. - E. Merck KG - Eli Lilly and Company - Bristol-Myers Squibb Company - Novartis AG - Bayer AG - AstraZeneca PLC - National Cancer Institute - Memorial Sloan Kettering Cancer Center - The University of Texas M. D. Anderson Cancer Center - Grupo Espanol de Tratamiento de Tumores Digestivos - Epidemiological and Clinical Research Information Network - European Organization for Research and Treatment of Cancer - Gruppo Oncologico del Nord-Ovest - NCIC Clinical Trials Group - Duke University For more information visit http://www.researchandmarkets.com/research/4jtbsc/metastatic
Technical Recap on Pharma Equities -- Research on Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu May 01, 8:16AM CDT
On Wednesday, April 30, 2014, the NASDAQ Composite ended at 4,114.56, up 0.27%, the Dow Jones Industrial Average advanced 0.27%, to finish the day at 16,580.84, and the S&P 500 closed at 1,883.95, up 0.30%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.95, up 0.14%, with the index advancing 3.87% in the previous three months. Investor-Edge has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly & Company (NYSE: LLY) and GlaxoSmithKline PLC (NYSE: GSK). Free technical research on BMY, AZN, LLY and GSK can be downloaded upon signing up at:
Global Metastatic Prostate Cancer Clinical Trials Review 2014: Espy the 20 Leading Companies/Institutions
M2 - Thu May 01, 7:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/thv65g/metastatic) has announced the addition of the "Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Prostate Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Johnson & Johnson - Astellas Pharma Inc. - AstraZeneca PLC - Medivation, Inc. - Sanofi - Ipsen S.A. - Bristol-Myers Squibb Company - Pfizer Inc. - Novartis AG - Eli Lilly and Company - National Cancer Institute - European Organization for Research and Treatment of Cancer - Memorial Sloan Kettering Cancer Center - Barbara Ann Karmanos Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Southwest Oncology Group - OHSU Knight Cancer Institute - Swiss Group for Clinical Cancer Research - National Prostate Cancer Treatment Group - UNICANCER Group For more information visit http://www.researchandmarkets.com/research/thv65g/metastatic
Research and Markets: Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
Business Wire - Thu May 01, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9fbq3/organ) has announced the addition of the "Worldwide Organ Preservation Solutions Market 2013 - 2019" report to their offering.
Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - Thu May 01, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ
Beyond Bristol's Big Dividend: 3 Things Investors Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Bristol-Myers ' first-quarter sales appear tepid at best as revenue fell 1% to $3.8 billion, although its juicy dividend of 2.9% has certainly been attractive to income investors.However, there are some encouraging signs that Bristol may be...
Earnings Roundup: Is AbbVie on Borrowed Time?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 1:30PM CDT
AbbVie 's better-than-hoped first-quarter earnings has shares rallying since mid-month. However, shares remain down on the year on concerns that its new hepatitis C drug won't live up to expectations and be able to blunt the eventual risk of patent...
Bristol-Myers Squibb's (BMY) CEO John Elicker on Q1 2014 Earnings - Call Transcript
at The Street - Wed Apr 30, 11:26AM CDT
Bristol-Myers Squibb Company (BMY) Q1 2014 Earnings Conference Call - April 29, 2014 9:00 AM ET
Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials Review 2014
M2 - Wed Apr 30, 11:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k5m6xs/metastatic) has announced the addition of the "Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Transitional Cell Cancer (Urothelial Cell Cancer) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Transitional Cell Cancer (Urothelial Cell Cancer). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Co., Ltd. - Boehringer Ingelheim GmbH - Biotest AG - Astellas Pharma Inc. - Altor BioScience Corporation - National Cancer Institute - The University of Chicago - European Organization for Research and Treatment of Cancer - Icahn School of Medicine at Mount Sinai - Memorial Sloan Kettering Cancer Center - Barts and The London NHS Trust - The Wales Cancer Trials Unit - Northern California Cancer Center - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/k5m6xs/metastatic
Papillary Renal Cell Carcinoma Clinical Trials Review 2014
M2 - Wed Apr 30, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2qftt/papillary_renal) has announced the addition of the "Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" report to their offering. Papillary Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Papillary Renal Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Papillary Renal Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Papillary Renal Cell Carcinoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Novartis AG - GlaxoSmithKline plc - Eli Lilly and Company - Bristol-Myers Squibb Company - AstraZeneca PLC - Astellas Pharma Inc. - National Cancer Institute - Fox Chase Cancer Center - Memorial Sloan Kettering Cancer Center - UNICANCER Group - Austrian Urogynecology Working Group - Ohio State University Comprehensive Cancer Center - Fred Hutchinson Cancer Research Center - Children's Oncology Group For more information visit http://www.researchandmarkets.com/research/m2...lary_renal
Are Exosomes the Next PD-1 in Cancer Research?
ACCESSWIRE - Wed Apr 30, 9:01AM CDT
Whitefish, MT / April 30, 2014 / PD-1, or programmed death protein 1, is certainly a hot button in the field of oncology, with the new immune checkpoint inhibitors pegged by many as part of a wave of new therapies to meet areas of great unmet medical need in cancer treatment. Merck & Co. (NYSE: MRK) has received the coveted FDA "breakthrough" designation for its PD-1 inhibitor lambrolizumab, putting it in a position to vie for the lead with Bristol-Myers Squibb's (NYSE: BMY) antibody nivolumab. Both companies have reported impressive results on their drugs for several cancer types, either as a monotherapy or in combination treatments, including melanoma and non-small cell lung cancer.
Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management
PRWeb - Wed Apr 30, 2:25AM CDT
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced highlights of its Chemical Development Summit, held April 23 - 24, 2014 at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey. The meeting featured a tour of the BMS high throughput lab, customer case studies, and discussions of best practices in high throughput research and data management.
Bristol, Merck Q1 sales soft
at Investor's Business Daily - Tue Apr 29, 5:42PM CDT
Bristol-Myers Squibb (BMY) said EPS rose 12% to 46 cents, beating views by 3 cents. But sales fell 1% to $3.8 bil, missing views of $3.9 bil. Bristol raised the low end of its full-year EPS guidance to $1.65-$1.80, but the midpoint is below analysts'...
